Clinical Update from a Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients with Metastatic Solid Tumors and Hematologic Malignancies

Conclusions:

• Enrolled heavily pre-treated end-stage oncology population with a variety of tumor types.
• Excellent safety profile with no drug related adverse events observed to date. All SAEs were classified as not related to SUPLEXA.
• Encouraging signs of clinical activity in various tumor types, consistent with broad preclinical in vitro activity.
• Exploratory CyTOF characterization of first 3 patient samples demonstrate
  • Circulating cytokines levels were modulated by SUPLEXA therapeutic cells.
  • SUPLEXA cell manufacturing resulted in similar immune populations.
  • T cells, NK cells and NKT Cells in SUPLEXA showed cytotoxic phenotypes.
  • SUPLEXA cell therapy improved markers of immune health over initial time points.